News/ News/ Oncology/ UK & Europe EU cancer drugs rejection shows contrasts with FDA Andrew McConaghie CHMP, ema, neratinib, Puma Biotechnology 0 Comment Europe’s expert medicines panel has rejected Puma Biotechnology’s breast cancer drug neratinib, citing limitations in its efficacy and safety Share X EU cancer drugs rejection shows contrasts with FDA https://pharmaphorum.com/news/eu-rejection-cancer-drugs-shows-differences-fda/
